AZN HealthcareBeta data

AstraZeneca PLC

$183.88-1.45%

Price as of close on Nov 3, 2026 · Financials updated Nov 1, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - General
Country: United Kingdom
Market cap: 285.2B USD
Enterprise value: 311.4B USD
Full-time employees: 96,100

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: less short-term liquidity (current ratio 1.01 vs a peer median of 2.59)less liquidity (current ratio 1.01 vs peers 2.59)
Drawback: more debt relative to equity (0.66× vs a peer median of 0.22×)more debt vs equity (0.66× vs peers 0.22×)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #291 of 1,157 healthcare companies (top 26%)

See how it ranks against its peers

Worth knowing

Operating margin at a 6-year high. 23% in 2025, the best of the last 6 years.
AstraZeneca kept 23% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Profits growing faster than sales. Since 2022: revenue +32%, operating profit +266%.
Since 2022, AstraZeneca's revenue grew 32% while operating profit grew 266%: each extra dollar of sales is adding more profit.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $26.6B in 2020 to $58.7B in 2025.
AstraZeneca's fiscal-year revenue rose in each of the five years to 2025, from $26.6B to $58.7B.

StockQuotient Score

63/ 100

Oct 5 64 → Nov 4 63 (-1)

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

66/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ Earnings yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield3.8%

Yahoo Finance · trailing 12 monthsReported value30% base weight · Z-score 1.60Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.8%

Yahoo Finance · trailing 12 monthsReported value50% base weight · Z-score 0.70Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.1%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield18.1%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

64/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 4.0%

Why

Stronger than most peers on:

▲ EPS growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth45.3%

Yahoo Finance · fiscal year to Dec 2025Reported value33% base weight · Z-score 1.19Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth9.8%

SEC filings (IFRS mapped) · 3 years to Dec 2025Reported value33% base weight · Z-score 0.47Sector median: 0.0584 · MAD: 0.0840

Revenue growth8.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 0.26Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

86/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 3.4 points to 23.4%

Why

Stronger than most peers on:

▲ ROA
▲ Operating margin
▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin23.4%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 1.34Sector median: 0.0706 · MAD: 0.1217

Return on assets9.0%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 1.36Sector median: 0.0166 · MAD: 0.0537

Return on invested capital15.0%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 1.02Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin81.8%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity22.6%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Beta
▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.21

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.22Sector median: 0.6250 · MAD: 0.3380

Current ratio1.01×

Yahoo FinanceReported value33% base weight · Z-score -1.14Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.66×

Yahoo FinanceReported value33% base weight · Z-score -2.16Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about AstraZeneca

Is AstraZeneca getting weaker?: Its latest SEC filing (Feb 24, 2026) got stronger: operating margin rose 3.4 points to 23.4%. Its overall score is unchanged at 63/100 since Oct 28, 2026.
How is AstraZeneca valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 66/100 against 1,393 healthcare peers. Earnings yield 3.8% vs a peer median of 1.5% (stronger than 69% of peers).Earnings yield 3.8% vs peers 1.5% (stronger than 69% of peers).
Is AstraZeneca growing?: Yes, faster than most of its peers. Growth scores 64/100 against 1,393 healthcare peers. Earnings per share growth 45.3% vs a peer median of 9.8% (stronger than 79% of peers).Earnings per share growth 45.3% vs peers 9.8% (stronger than 79% of peers).
How profitable is AstraZeneca?: More profitable than most of its peers. Profitability scores 86/100 against 1,393 healthcare peers. Return on assets 9.0% vs a peer median of 1.7% (stronger than 88% of peers).Return on assets 9.0% vs peers 1.7% (stronger than 88% of peers).
How risky is AstraZeneca?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.21 vs a peer median of 0.63 (stronger than 90% of peers).Beta 0.21 vs peers 0.63 (stronger than 90% of peers). Current ratio 1.01× vs a peer median of 2.59× (weaker than 90% of peers).Current ratio 1.01× vs peers 2.59× (weaker than 90% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Feb 24, 2026 · compared with the quarter ended Jun 30, 2025

Got stronger

Operating margin rose 3.4 points to 23.4%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	56.5B USD	58.7B USD	+4.0%
Net income (12 months)	8.3B USD	10.2B USD	+23.3%
Operating margin	20.0%	23.4%	+3.4 pts
Free cash flow (12 months)	11.2B USD	11.8B USD	+5.3%
Debt	32.8B USD	29.6B USD	−9.8%
Cash	7.1B USD	5.7B USD	−19.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	66.8%	72.1%	82.0%	81.1%	81.9%	▲ 0.8 pts
Operating margin	2.8%	8.5%	17.9%	18.5%	23.4%	▲ 4.9 pts
Net margin	0.3%	7.4%	13.0%	13.0%	17.4%	▲ 4.4 pts
Return on assets (ROA)	0.1%	3.4%	5.9%	6.8%	9.0%	▲ 2.2 pts
Return on equity (ROE)	0.3%	8.9%	15.2%	17.2%	21.0%	▲ 3.8 pts
Free cash flow margin	13.0%	19.7%	19.6%	18.4%	20.0%	▲ 1.7 pts
Current ratio	1.16×	0.86×	0.82×	0.93×	0.94×	▲ 1.2%
Quick ratio	0.76×	0.68×	0.64×	0.74×	0.72×	▼ 1.8%
Debt to equity	0.78×	0.79×	0.73×	0.74×	0.61×	▼ 18%
Interest coverage	0.81×	2.79×	5.04×	5.74×	8.11×	▲ 41%

AZN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: less short-term liquidity (current ratio 1.01 vs a peer median of 2.59)less liquidity (current ratio 1.01 vs peers 2.59)

Drawback: more debt relative to equity (0.66× vs a peer median of 0.22×)more debt vs equity (0.66× vs peers 0.22×)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #291 of 1,157 healthcare companies (top 26%)

See how it ranks against its peers

Worth knowing

Operating margin at a 6-year high. 23% in 2025, the best of the last 6 years.

AstraZeneca kept 23% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.

Profits growing faster than sales. Since 2022: revenue +32%, operating profit +266%.

Since 2022, AstraZeneca's revenue grew 32% while operating profit grew 266%: each extra dollar of sales is adding more profit.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $26.6B in 2020 to $58.7B in 2025.

AstraZeneca's fiscal-year revenue rose in each of the five years to 2025, from $26.6B to $58.7B.

Questions investors ask about AstraZeneca

Is AstraZeneca getting weaker?

Its latest SEC filing (Feb 24, 2026) got stronger: operating margin rose 3.4 points to 23.4%. Its overall score is unchanged at 63/100 since Oct 28, 2026.

How is AstraZeneca valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 66/100 against 1,393 healthcare peers. Earnings yield 3.8% vs a peer median of 1.5% (stronger than 69% of peers).Earnings yield 3.8% vs peers 1.5% (stronger than 69% of peers).

Is AstraZeneca growing?

Yes, faster than most of its peers. Growth scores 64/100 against 1,393 healthcare peers. Earnings per share growth 45.3% vs a peer median of 9.8% (stronger than 79% of peers).Earnings per share growth 45.3% vs peers 9.8% (stronger than 79% of peers).

How profitable is AstraZeneca?

More profitable than most of its peers. Profitability scores 86/100 against 1,393 healthcare peers. Return on assets 9.0% vs a peer median of 1.7% (stronger than 88% of peers).Return on assets 9.0% vs peers 1.7% (stronger than 88% of peers).

How risky is AstraZeneca?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.21 vs a peer median of 0.63 (stronger than 90% of peers).Beta 0.21 vs peers 0.63 (stronger than 90% of peers). Current ratio 1.01× vs a peer median of 2.59× (weaker than 90% of peers).Current ratio 1.01× vs peers 2.59× (weaker than 90% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

56.5B USD

58.7B USD

+4.0%

Net income (12 months)

8.3B USD

10.2B USD

+23.3%

Operating margin

20.0%

23.4%

+3.4 pts

Free cash flow (12 months)

11.2B USD

11.8B USD

+5.3%

Debt

32.8B USD

29.6B USD

−9.8%

Cash

7.1B USD

5.7B USD

−19.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

66.8%

72.1%

82.0%

81.1%

81.9%

▲ 0.8 pts

Operating margin

2.8%

8.5%

17.9%

18.5%

23.4%

▲ 4.9 pts

Net margin

0.3%

7.4%

13.0%

17.4%

▲ 4.4 pts

Return on assets (ROA)

0.1%

3.4%

5.9%

6.8%

9.0%

▲ 2.2 pts

Return on equity (ROE)

0.3%

8.9%

15.2%

17.2%

21.0%

▲ 3.8 pts

Free cash flow margin

13.0%

19.7%

19.6%

18.4%

20.0%

▲ 1.7 pts

Current ratio

1.16×

0.86×

0.82×

0.93×

0.94×

▲ 1.2%

Quick ratio

0.76×

0.68×

0.64×

0.74×

0.72×

▼ 1.8%

Debt to equity

0.78×

0.79×

0.73×

0.74×

0.61×

▼ 18%

Interest coverage

0.81×

2.79×

5.04×

5.74×

8.11×

▲ 41%